Takeda’s Ninlaro fails phase 3 amyloidosis trialTakeda is discontinuing a trial of its drug Ninlaro in systemic light-chain AL amyloidosis after it did not Share XTakeda’s Ninlaro fails phase 3 amyloidosis trialhttps://pharmaphorum.com/news/takedas-ninlaro-fails-phase-3-amyloidosis-trial/
Takeda’s myeloma drug Ninlaro approved in EuropeTakeda has gained European Union approval of its multiple myeloma drug Ninlaro for second line use – joining Share XTakeda’s myeloma drug Ninlaro approved in Europehttps://pharmaphorum.com/news/takedas-myeloma-drug-ninlaro-approved-europe/
